The Weight Loss Industry's Wild Ride: Why Novo Nordisk's Ziltivekimab Matters The recent slump in weight loss drug stocks has left investors and analysts puzzled.
Beneath the surface, however, lies a more complex story – one of efficacy and ethics questions surrounding these new medications.
At the center is Novo Nordisk's ziltivekimab, an experimental treatment designed to combat obesity.